Assessment of Sedation Quality and Maternal–Fetal Safety Using Remifentanil versus Midazolam in Monitored Anesthesia Care during Diagnostic Hysteroscopy Authors: Narayan Hari Sharma, Aditya Singh Chauhan, Divya Sinha, Sourabh Shrivastava Published: 2025 ABSTRACT Background:Monitored anesthesia care (MAC) is increasingly utilized in diagnostic hysteroscopy to ensure patient comfort while maintaining safety. Among various agents, remifentanil and midazolam are commonly employed, but comparative data on their sedation quality and maternal–fetal safety profiles during hysteroscopy in reproductive-age women remain limited.Methods:This prospective, randomized, controlled trial included 120 women undergoing diagnostic hysteroscopy. Participants were randomized into two groups: Group R (remifentanil infusion at 0.05–0.1 µg/kg/min) and Group M (midazolam bolus 0.05 mg/kg followed by 0.02 mg/kg as needed). Primary outcomes were sedation quality (Ramsay Sedation Score [RSS], patient and surgeon satisfaction), and secondary outcomes included hemodynamic stability, recovery time, and fetal safety indicators (serum β-hCG and uterine perfusion on Doppler ultrasonography pre- and post-procedure).Results:Group R had significantly better sedation depth (RSS: 3.8 ± 0.6 vs. 2.9 ± 0.5, P < 0.001), shorter recovery time (11.2 ± 2.1 min vs. 24.7 ± 3.6 min, P < 0.001), and higher patient satisfaction (94.1% vs. 78.3%, P = 0.018). Hemodynamic parameters remained stable in both groups. No significant difference was found in fetal safety markers (serum β-hCG: P = 0.41; uterine perfusion index: P = 0.57).Conclusion:Remifentanil provides superior sedation quality and faster recovery without compromising maternal–fetal safety compared to midazolam during MAC for diagnostic hysteroscopy. It is a viable alternative for short gynecological procedures in reproductive-age women. INTRODUCTION Diagnostic hysteroscopy is a minimally invasive procedure used extensively to evaluate intrauterine pathology in women with abnormal uterine bleeding, infertility, or recurrent pregnancy loss. Ensuring adequate sedation and analgesia is critical, particularly when performed in outpatient settings under monitored anesthesia care (MAC).[1] MAC allows spontaneous ventilation while maintaining a high level of procedural comfort and safety. Among commonly used sedatives, midazolam, a benzodiazepine, offers anxiolysis and amnesia with moderate analgesic properties. However, its longer recovery profile and respiratory depressive effects have raised concerns.[2] Remifentanil, a potent short-acting µ-opioid receptor agonist, has emerged as an attractive alternative due to its rapid onset, titratability, and swift elimination.[3] These pharmacokinetic advantages make it suitable for short procedures like diagnostic hysteroscopy.[4] While both agents are used widely, direct comparisons in the context of hysteroscopy remain limited. Additionally, data on maternal–fetal safety, particularly in women of reproductive age undergoing diagnostic procedures with potential implications on fertility, are sparse. Concerns regarding altered uterine perfusion and hormonal changes following sedative use warrant detailed investigation.[5] Therefore, this study aimed to evaluate and compare the sedation quality and maternal–fetal safety of remifentanil versus midazolam in women undergoing MAC for diagnostic hysteroscopy. MATERIALS AND METHODS Study design and setting This was a prospective, randomized, controlled study conducted at the Department of Anaesthesiology and Obstetrics and Gynaecology at a tertiary care hospital from July 2023 to March 2024. Participants A total of 120 female patients aged 20–40 years undergoing elective diagnostic hysteroscopy were enrolled. Inclusion criteria were: ASA I or II, positive β-hCG indicating early pregnancy suspicion or assisted conception monitoring, and informed consent. Exclusion criteria included known hypersensitivity to study drugs, psychiatric illness, chronic opioid or benzodiazepine use, and cardiovascular instability. Randomization and blinding Participants were randomized into two equal groups (n = 60 each) using a computer-generated randomization list. The anesthesiologist administering sedation was aware of group allocation; however, outcome assessors and surgeons were blinded. Intervention Group R: Remifentanil infusion initiated at 0.05 µg/kg/min and titrated to effect (max 0.1 µg/kg/min). Group R: Remifentanil infusion initiated at 0.05 µg/kg/min and titrated to effect (max 0.1 µg/kg/min). Group M: Midazolam bolus 0.05 mg/kg followed by additional doses of 0.02 mg/kg as needed. Group M: Midazolam bolus 0.05 mg/kg followed by additional doses of 0.02 mg/kg as needed. All patients received supplemental oxygen (4 L/min via nasal cannula). Standard monitoring included ECG, pulse oximetry, and noninvasive blood pressure every 2 minutes. Outcomes Primary outcomes: Sedation quality (Ramsay Sedation Score [RSS]), patient and surgeon satisfaction (VAS scale 0–10). Primary outcomes: Sedation quality (Ramsay Sedation Score [RSS]), patient and surgeon satisfaction (VAS scale 0–10). Secondary outcomes: Hemodynamic stability, recovery time (Aldrete score ≥ 9), uterine artery Doppler flow indices (PI, RI), and serum β-hCG (baseline and 2 hours post-procedure). Secondary outcomes: Hemodynamic stability, recovery time (Aldrete score ≥ 9), uterine artery Doppler flow indices (PI, RI), and serum β-hCG (baseline and 2 hours post-procedure). Statistical analysis Data were analyzed using SPSS v26.0. Continuous variables were presented as mean ± SD and compared using independent t-tests. Categorical data were expressed in percentages and compared using Chi-square tests. A P value <0.05 was considered statistically significant. RESULTS Demographic characteristics Both groups were comparable in age, BMI, and ASA physical status [Table 1]. Table 1Baseline demographics and key outcomesParameterGroup R (remifentanil)Group M (midazolam) P Age (years)32.1±4.531.6±4.70.58BMI (kg/m2)24.8±3.125.2±3.30.63RSS Score3.8±0.62.9±0.5<0.001Recovery time (min)11.2±2.124.7±3.6<0.001Patient satisfaction (VAS)9.1±0.77.6±1.10.018β-hCG (mIU/mL) change-0.8±1.4-0.9±1.20.41Uterine PI post-procedure1.14±0.211.12±0.190.57BMI=Body mass index, RSS=Ramsay Sedation Score, VAS=value-added service, β-hCG=beta-human chorionic gonadotropin, PI=pulsatility index Baseline demographics and key outcomes BMI=Body mass index, RSS=Ramsay Sedation Score, VAS=value-added service, β-hCG=beta-human chorionic gonadotropin, PI=pulsatility index Sedation quality Group R demonstrated significantly higher mean RSS scores (3.8 ± 0.6 vs. 2.9 ± 0.5, P < 0.001). Patient satisfaction was higher in Group R (VAS: 9.1 ± 0.7) compared to Group M (7.6 ± 1.1, P = 0.018). Surgeon satisfaction also favored remifentanil (8.8 ± 0.5 vs. 7.9 ± 1.0, P = 0.027). Recovery profile Time to full recovery was significantly shorter in Group R (11.2 ± 2.1 minutes) than in Group M (24.7 ± 3.6 minutes, P < 0.001). Hemodynamic parameters No significant hypotension or bradycardia was observed in either group. Mean heart rate and blood pressure remained within physiological limits. Maternal–fetal safety Pre- and post-procedure serum β-hCG levels did not show significant changes between the groups (P = 0.41). Uterine artery pulsatility and resistance indices showed no significant differences pre- and post-procedure in both groups (PI: 1.14 ± 0.21 vs. 1.12 ± 0.19, P = 0.57). DISCUSSION This study demonstrates that remifentanil offers superior sedation quality and faster recovery compared to midazolam during MAC for diagnostic hysteroscopy, without compromising maternal–fetal safety. These findings are consistent with prior studies evaluating remifentanil in outpatient gynecologic procedures.[6] The improved RSS scores and higher satisfaction ratings in the remifentanil group align with prior literature showing its efficacy in achieving deeper yet controlled sedation.[7] Midazolam, though effective, is associated with prolonged recovery due to its longer elimination half-life.[8] A key concern in using any sedative in reproductive-age women is potential impairment of uterine perfusion or hormonal imbalance. Our data showed no significant difference in uterine artery flow indices or serum β-hCG, indicating preserved maternal–fetal physiology. Previous studies have also found remifentanil to exert minimal effect on uteroplacental circulation, especially in low infusion doses.[9] Hemodynamic stability across both groups is reassuring, suggesting the safety of both drugs when appropriately titrated. However, the quicker recovery associated with remifentanil may enhance outpatient efficiency, reduce PACU stay, and lower costs.[10] Limitations of this study include the absence of long-term follow-up and the exclusion of patients undergoing operative hysteroscopy. Future studies should include broader populations and investigate other outcome measures, such as memory recall and anxiety reduction. CONCLUSION Remifentanil-based MAC provides superior sedation depth, enhanced patient and surgeon satisfaction, and faster recovery when compared to midazolam for diagnostic hysteroscopy in reproductive-age women. Both agents appear safe concerning maternal–fetal outcomes, but remifentanil may be preferred in high-throughput or fertility-sensitive settings. Conflicts of interest There are no conflicts of interest.